



iTrack™ Advance to be Featured at the 10th World Glaucoma Congress

California, USA, June 26, 2023 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that its proprietary iTrack™ technology portfolio for canaloplasty, an implant-free, minimally invasive surgical procedure for glaucoma, will be featured during the official program of the 10th World Glaucoma Congress (“WGC”), taking place June 28-July 1, 2023, in Rome, Italy.

A summary of the iTrack™ scientific poster programming at the 10th World Glaucoma Congress is outlined below:

POSTER 1:

Global Longitudinal Data Registry on the Role of Canaloplasty for Treatment of Glaucoma - One Year Results

David Lubeck (USA); Nathan Kerr (Australia); Keith Barton (UK); Iqbal “Ike” Ahmed (Canada)

POSTER 2:

Endothelial Cell Density and Loss Following Ab-Interno Canaloplasty in Patients with Mild-Moderate Glaucoma as Compared to Severe Glaucoma

David Lubeck (USA); Robert Noecker (USA)

POSTER 3:

24-Month Evaluation of Endothelial Cell Density and Loss Following Ab-Interno Canaloplasty

David Lubeck (USA); Robert Noecker (USA)

POSTER 4:

6-Year Efficacy and Safety of iTrack Ab-interno Canaloplasty as a Standalone Procedure and Combined with Cataract Surgery in Primary Open-Angle Glaucoma

Norbert Körber (Germany); Simon Ondrejka (Germany)



On Friday June 30 (7.30/08.30am CET), Nova Eye will host an official symposium “Canaloplasty: lighting the way in stent-free, tissue-sparing MIGS” which will spotlight its new canaloplasty device, iTrack™ Advance. The symposium will be moderated by Dr. Iqbal “Ike” Ahmed and will feature a global panel of surgeons including: Antonio Fea, Italy; Jose Maria Martinez de la Casa, Spain; Karl Mercieca, Germany; Ticiana de Fransesco, Brazil, Neeru Vallabh, UK, Andrew Tatham, UK, Norbert Koerber, Germany and Robert Noecker, USA. Registration is open to all delegates of the 10th World Glaucoma Congress. More information is available at www.nova-eye.com/WGC

Nova Eye Medical will present the latest generation iTrack™ Advance canaloplasty device during the 10th World Glaucoma Congress at exhibit #D148.

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include the iTrack™ portfolio of canaloplasty devices for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the treatment of severe or complex glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

ABOUT CANALOPLASTY

First introduced in 2008, canaloplasty is a surgical treatment for glaucoma that targets the main sites of outflow resistance in the conventional outflow pathway: the trabecular meshwork, Schlemm’s canal, and the distal collector channels. Based on the same



principles as angioplasty, a flexible microcatheter is cannulated 360 degrees around Schlemm's canal during the procedure to manually break and remove blockages. Next, viscoelastic fluid is injected into Schlemm's canal as the microcatheter is withdrawn to dilate the distal outflow system and to improve the function of the trabecular meshwork.

iTrack™ and iTrack™ Advance have a US Food and Drug Administration (FDA) 510(k) and CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma.

The iTrack™ Advance canaloplasty device has been cleared for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma.

The iTrack™ canaloplasty microcatheter has been cleared for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma. The iTrack™ canaloplasty microcatheter is not cleared for the ab-interno surgical technique in the United States.

For additional information about the *iTrack™ Advance*, including safety information, please visit: <https://itrack-advance.com/us>

Images are available at this link: <https://bit.ly/3GANwyR>

For media enquiries, please contact:

Kate Hunt: Nova Eye Chief Commercial Officer - khunt@nova-eye.com

Giorgio Pirazzini: GP Communications – giorgio@gpcommunications.eu